Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 4, 2011, Pages 258-267

  Johansson, S ^a   Cullberg, M ^a   Eriksson, U G ^a   Elg, M ^a   Duner K ^a   Jensen, E ^a   Wollbratt, M ^a   Wahlander K ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

AR H067637; AZD0837; Direct thrombin inhibitor; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AR H 067637; AR H 069927; AZD 0837; DRUG METABOLITE; ECARIN; PLACEBO; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; EX VIVO STUDY; FOOD DRUG INTERACTION; GINGIVA BLEEDING; HEADACHE; HEMATOCHEZIA; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; SINGLE BLIND PROCEDURE; THROMBIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AMIDINES; ANTICOAGULANTS; AREA UNDER CURVE; AZETIDINES; HUMANS; MALE; SINGLE-BLIND METHOD; THROMBIN;

EID: 79955976183     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201465     Document Type: Article

References (16)

1. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009; 48: 1-22.
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther Mand Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 160-198.
3. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 546-592.
4. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003; 41: 1633-1652.
5. Brass LF. Thrombin and platelet activation. Chest. 2003; 124: S18-S25.
6. Eriksson UG, Bredberg U, Gislén K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol. 2003; 59: 35-43. (Pubitemid 36702757)
7. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sörensen H. Effects of melagatran, a new low-molecularweight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost. 1998; 79: 110-118. (Pubitemid 28037068)
8. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98: 155-162. (Pubitemid 47078782)
9. Olsson SB, Rasmussen LH, Tveit A, Jensen E, Wessman P, Panfilov S, Wåhlander K. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost. 2010; 103: 604-612.
10. Lip GYH, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KFC and on behalf of the Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomised dose-guiding, safety and tolerability study of four doses of AZD0837 versus vitamin K antagonists. Eur Heart J. 2009; 30: 2897-2907.
11. Pehrsson S, Johanson K, Kjaer M and Elg M. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. Thromb Haemost. 2010; 104: 1242-1249.
12. Andersson S, Hofmann W, Nordling A, Li X-Q, Nivelius S, Andersson TB, Ingelman-Sundberg M, Johansson I. Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagtran and benzamidoxime. Drug Metab Dispos. 2005; 33: 570-578. (Pubitemid 40393201)
13. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33: 4-15. (Pubitemid 37449290)
14. Schutzer KM, Svensson MK, Zetterstrand S, Eriksson UG, Whålander K. Reversible elevations of serum creatinine levels but no effect on glomerular filtration during treatment with the direct thrombin inhibitor AZD0837. Eur J Clin Pharmacol. 2010; 66: 903-910.
15. Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson Å, Karlson BW, Sheth SB, Held P.Areview of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res. 2005; 115: 9-18. (Pubitemid 39572749)
16. Deinum J, Mattsson C, Inghardt T, Elg M. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637. Thromb Haemost. 2009; 101: 1051-1059.